Immunotherapy currently offers the brightest hope for cancer treatment. New developments with checkpoint inhibitors and co-stimulatory targets have enabled some stunning breakthroughs and high optimism for the sector.
Recently, there have been some incredibly exciting new therapies in areas such as CAR-T and Oncolytic Viral Immunotherapy. Our vision is to bring together the full community and provide a single meeting point for the whole value chain.
It is where science meets business to make immunotherapy the cornerstone of the fight against cancer.
For the third instalment of the World Immunotherapy Congress, we have introduced more content allowing us to delve deeper into the case studies, clinical trials and immunotherapy discovery than ever before. With two full tracks of content over the three days, covering oncology, non-oncology (infectious disease, inflammation, autoimmune disorders, organ transplant and neurological disease), oncolytics, cancer vaccines, safety, and efficacy, we are covering all bases.
As part of the Festival of Biologics, the World Immunotherapy Congress will be co-located with World Biosimilar Congress, European Antibody Congress and HPAPI World Congress. Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
We look forward to welcoming you to Basel.
29-31 October, Basel, Switzerland
Part of the